FALMOUTH, England, September 21, 2015 /PRNewswire/ --
IVF Bioscience today announced that it has acquired EmbryoTrans Biotech's intellectual property for the production of IVF media for animal species used during the in-vitro fertilisation (IVF) process. The transaction value has not been disclosed.
Commenting on the transaction, Bill Brown, IVF Bioscience's Chairman, said, "The acquisition of EmbryoTrans Biotech's IP is the starting point to our mission to become the number one animal IVF media provider. This acquisition positions us at the forefront of the emerging field of animal IVF improving pregnancy rates in animal reproduction. We are looking forward to developing more species specific media lines for the animal market."
Lotte Strøbech, CEO of EmbryoTrans Biotech said, "Embryotrans Biotech has been looking for the right partner with experience of the human IVF market for some time. We felt that a new approach was required for our industry; one where the same values of high quality, standardisation and accreditation in the human market were applied to the animal market. IVF Bioscience has over 23 years of experience in the development of products for the human market and has seven years' experience of successfully marketing in this highly competitive field. We have extensive connections with commercial laboratories as well as leading scientific research institutions allowing scientific validation through results from close collaboration."
IVF Bioscience will launch their first species specific media with the Bovine BO-IVF range. EmbryoTrans Biotech will continue to develop new products for IVF Bioscience under an exclusive agreement.
About IVF Bioscience
IVF Bioscience was formed by the founders of Research Instruments Limited, the largest global hardware provider for human IVF. IVF Bioscience aims to help develop the animal IVF market by improving yields through higher success rates.
Using the BO-IVF media system, laboratories can benefit from this extensive combined portfolio of knowledge of EmbryoTrans Biotech by achieving higher blastocyst rates, more robust blastocysts and thereby a higher pregnancy rate.
About EmbryoTrans Biotech (ETB)
The scientific team behind the development of media in EmbryoTrans Biotech is Lotte Strøbech, DVM, PhD and Birthe Avery, MD, PhD, DVSc. Dr. Strøbech is a Lab Director and Embryologist with 15+ years' experience in IVF media development. Also in this time, she has established collaborations and consulted internationally with acknowledged laboratory research facilities in Universities as well as in Medical Device and Livestock industries in Europe and North America.
Dr. Avery is former Associate Professor (now retired) from the Veterinary Faculty, University of Copenhagen. As Head of the IVF laboratory for 27 years, Dr. Avery was responsible for research, predominantly in bovine, porcine and equine in vitro embryo technology and is today Scientific Advisor to ETB.
The bovine protocol and media portfolio acquired by IVF Bioscience has been optimised and improved with results rendering often more than 50% blastocyst rates and higher quality embryos from unselected slaughterhouse oocytes, considerably higher than usually achieved blastocyst rates in bovine IVF systems. The same superiority in performance has also been confirmed in oocytes derived from Ovum Pick Up (OPU).
Lis Goulder, IVF Bioscience, tel +44(0)1326-372753, email firstname.lastname@example.org
SOURCE IVF Bioscience